Table of Contents  
EDITORIAL
Year : 2016  |  Volume : 4  |  Issue : 2  |  Page : 53

Platelet-rich plasma therapy in orthopedic clinical practice: "Again I ask the gentleman…"


Hiranandai Orthopaedic Medical Education (HOME), Dr. L H Hiranandani Hospital, Mumbai, Maharashtra, India

Date of Web Publication10-Nov-2016

Correspondence Address:
Vijay D Shetty
Dr. L H Hiranandani Hospital, Hill Side Avenue, Powai, Mumbai - 400 076, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2319-2585.193751

Rights and Permissions

How to cite this article:
Shetty VD. Platelet-rich plasma therapy in orthopedic clinical practice: "Again I ask the gentleman…". J Orthop Allied Sci 2016;4:53

How to cite this URL:
Shetty VD. Platelet-rich plasma therapy in orthopedic clinical practice: "Again I ask the gentleman…". J Orthop Allied Sci [serial online] 2016 [cited 2024 Mar 28];4:53. Available from: https://www.joas.in/text.asp?2016/4/2/53/193751

There has been a rapid increase in popularity of platelet-rich plasma (PRP) in orthopedic clinical practice in the last decade. While there have been a number of publications supporting the use of PRP in clinical use, there are also many publications, which do not support the efficacy of PRP in certain clinical conditions. However, it appears that these days, more and more orthopedic surgeons are taking an interest in meetings dedicated to the use of PRP in clinical practice.

Approximately 10 years ago, PRP used to be one product, a solution that had platelet count almost five times above the baseline, although at the same time many studies questioned the ideal concentration for a specific clinical condition. Over a period, things have changed and some researchers started questioning the contents of an ideal PRP solution for a particular indication. The presence of white blood cells (WBCs) in PRP is still a matter of huge debate. Some studies have shown that the WBCs in PRP can be harmful, particularly when used for intra-articular injections. We, now, have special PRP kits available in the market, which help making "leukocyte-poor PRP." Most recent studies have also highlighted on the harmful effects of some of the other contents of PRP.

Thus, "improving the efficacy of PRP" in clinical practice is the latest buzzword among the researchers. Most recent studies have also indicated that the presence of alpha-2 macroglobulin can improve the efficacy significantly. Efforts are being made to remove "bad" factors from the preparations and keep only "good" factors. The bad factors are identified through special tests such as enzyme-linked immunosorbent assay test. It is believed that the future will see the use of PRP with improved efficacy. For the moment, the jury is still out and PRP "nonbelievers" continue to question "PRP believers" regarding the use of PRP in clinical use.




 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article

 Article Access Statistics
    Viewed4395    
    Printed522    
    Emailed0    
    PDF Downloaded3412    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]